D. Gardner

发表

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.

G. Trainor, M. Covington, C. Decicco, 2005, Journal of medicinal chemistry.

The discovery of BMS-457, a potent and selective CCR1 antagonist.

W. Guo, C. Cavallaro, A. Tebben, 2013, Bioorganic & medicinal chemistry letters.

Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.

J. Barrish, C. Cavallaro, A. Tebben, 2014, Journal of medicinal chemistry.

Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.

Michael G. Yang, S. Mandlekar, A. Mathur, 2021, ACS medicinal chemistry letters.

CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.

G. Trainor, M. Covington, C. Decicco, 2002, Bioorganic & medicinal chemistry letters.

Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.

G. Trainor, M. Covington, C. Decicco, 2004, Bioorganic & medicinal chemistry letters.

Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling.

J. Tokarski, D. Xie, N. Araníbar, 2017, MedChemComm.

Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.

G. Trainor, M. Covington, C. Decicco, 2004, Bioorganic & medicinal chemistry letters.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.

I. Kariv, S. Mandlekar, A. Tebben, 2008, Bioorganic & medicinal chemistry letters.

From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.

A. Tebben, P. Carter, J. Duncia, 2008, Bioorganic & medicinal chemistry letters.

Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR.

Eric T Baldwin, Martin C. Wright, Andrew J Tebben, 2015, Journal of molecular biology.

Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors.

J. Wityak, G. Trainor, R. Copeland, 2004, Bioorganic & medicinal chemistry letters.

Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672.

Michael G. Yang, Michael A. Galella, J. Barrish, 2019, ACS medicinal chemistry letters.